PT - JOURNAL ARTICLE AU - da Silva Francisco, Ronaldo AU - Benites, L. Felipe AU - Lamarca, Alessandra P AU - de Almeida, Luiz G P AU - Hansen, Alana Witt AU - Gularte, Juliana Schons AU - Demoliner, Meriane AU - Gerber, Alexandra L AU - de C Guimarães, Ana Paula AU - Antunes, Ana Karolina Eisen AU - Heldt, Fagner Henrique AU - Mallmann, Larissa AU - Hermann, Bruna AU - Ziulkoski, Ana Luiza AU - Goes, Vyctoria AU - Schallenberger, Karoline AU - Fillipi, Micheli AU - Pereira, Francini AU - Weber, Matheus Nunes AU - de Almeida, Paula Rodrigues AU - Fleck, Juliane Deise AU - Vasconcelos, Ana Tereza R AU - Spilki, Fernando Rosado TI - Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil AID - 10.1101/2021.01.21.21249764 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.21.21249764 4099 - http://medrxiv.org/content/early/2021/01/26/2021.01.21.21249764.short 4100 - http://medrxiv.org/content/early/2021/01/26/2021.01.21.21249764.full AB - Emergence of novel SARS-CoV-2 lineages are under the spotlight of the media, scientific community and governments. Recent reports of novel variants in the United Kingdom, South Africa and Brazil (B.1.1.28-E484K) have raised intense interest because of a possible higher transmission rate or resistance to the novel vaccines. Nevertheless, the spread of B.1.1.28 (E484K) and other variants in Brazil is still unknown. In this work, we investigated the population structure and genomic complexity of SARS-CoV-2 in Rio Grande do Sul, the southernmost state in Brazil. Most samples sequenced belonged to the B.1.1.28 (E484K) lineage, demonstrating its widespread dispersion. We were the first to identify two independent events of co-infection caused by the occurrence of B.1.1.28 (E484K) with either B.1.1.248 or B.1.91 lineages. Also, clustering analysis revealed the occurrence of a novel cluster of samples circulating in the state (named VUI-NP13L) characterized by 12 lineage-defining mutations. In light of the evidence for E484K dispersion, co-infection and emergence of VUI-NP13L in Rio Grande do Sul, we reaffirm the importance of establishing strict and effective social distancing measures to counter the spread of potentially more hazardous SARS-CoV-2 strains.HighlightsThe novel variant B.1.1.28 (E484K) previously described in Rio de Janeiro is currently spread across the southernmost state of Brazil;The novel variant VUI-NP13L was also identified by causing a local outbreak in Rio Grande do Sul;B.1.1.28 (E484K) is able to establish successful coinfection events co-occurring simultaneously with different lineages of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was developed in the frameworks of Rede Corona-omica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP = 01.20.0029.000462/20, CNPq = 404096/2020-4). The study was also supported by Corona-omica-RJ (FAPERJ = E-26/210.179/2020). A.T.R.V. is supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (303170/2017-4) and FAPERJ (E-26/202.903/20). F.R.S is a CNPq fellow (302668/2018-7). R.S.F.J is a recipient of a graduate fellowship from CNPq. A.P.L and L.F.B are granted a post-doctoral scholarship (DTI-A) from CNPq. J.S.L., M.D., A.K.E.A., K.S. are recipients of CAPES scholarships; F.H.H., B.H., V.G. and M.F. are supported by CNPq grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. This study was approved by the National Committee of Research Ethics and the Institutional Ethical Review Board of the Universidade de Feevale (protocol number: 33202820.7.1001.5348), following Brazilian regulations and international ethical standards. 2. Decision made: ethical approval was given.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNGS data generated in our study is publicly available in Gisaid (www.gisaid.org), and the access identifiers are listed in Supplementary Material.